Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Atazanavir/Ritonavir in HIV-1 Infected Subjects with Elevated Lipids
NCT00120393Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2004
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of atazanavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Percent change from baseline in fasting non-HDL cholesterol at 12 weeks. Started Jan 2004; status: completed.
02
Drugs
atazanavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00120393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120393.